BD Spinoff Embecta Hosts Virtual Investor Event; Discloses Insulin Patch Pump Program for T2DM

Embecta hosted a virtual investor event (slides; webcast) where management provided an overview of the company in terms of the global diabetes landscape, its position in the market, benefits of the spin-off, and global growth opportunities. Recall, in May 2021, BD announced plans to spin off its diabetes business as an independent, publicly-traded company (previous FENIX insight) and in February 2022, the company’s board of directors approved the planned spinoff (view press release). Of note, during the investor event, Embecta disclosed that the company is developing an insulin patch pump designed to reduce adoption barriers for individuals with T2DM. Below, FENIX provides highlights and insights from the presentation as it relates to the patch pump device.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.